Entresto ® is reimbursed for the treatment of adult patients with chronic heart failure with reduced ejection fraction in Belgium.
Sacubitril/valsartan, a first-in-class ARNI, delivers simultaneous inhibition of neprilysin and blockade of the AT1 receptor. Sacubitril/valsartan is a sodium salt complex comprising sacubitril (AHU377), a prodrug, which is further metabolized to the...
ENTRESTO ® is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. ENTRESTO is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic...
Together for Better In the fight against heart failure condition, we work our hardest every day to develop innovative and effective medication to sustain a better life, keeping the patient in mind. We are aware that the result of...